<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709029</url>
  </required_header>
  <id_info>
    <org_study_id>FMASU MS 32/2020</org_study_id>
    <nct_id>NCT04709029</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Versus Intrathecal Dexamethazone on Postdural Puncture Headache</brief_title>
  <official_title>Effect of Intravenous Versus Intrathecal Dexamethazone in Bupivacaine Spinal Anesthesia on Postdural Puncture Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted at Ain Shams University Hospital in Operating Theatre after&#xD;
      ethical committe approval number (MS 32/ 2020). It is a prospective randomized controlled&#xD;
      study will be done on patients undergoing lower abdominal and lower limb surgeries under&#xD;
      spinal anethesia,Eligible patients will be randomized by computer system to one of two&#xD;
      groups, either intravenous dexamethazzoe 8 mg with intrathecal heavy bupivacaine 0.5% or&#xD;
      intrathecal 4mg dexamethazone with intrathecal heavy bupivacaine 0.5%. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly divided into two equal groups: Group 1: patients receive&#xD;
      intrathecal 3 ml bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10&#xD;
      ml saline. Group 2: patients receive intrathecal 3 ml bupivacaine 0. 5% + 4 mg (1 ml)&#xD;
      dexamethazone + intravenous 10 ml normal saline. Upon patients' arrival into the operating&#xD;
      room, peripheral oxygen saturation (SPO2), ECG, pulse rate (PR), and systolic and diastolic&#xD;
      blood pressures will be monitored one of the researchers and recorded every 5 minutes till&#xD;
      the end of surgery. In a sitting position and with antiseptic techniques, 25 G Quincke needle&#xD;
      was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study&#xD;
      drugs were given by an anesthesiologist not not aware of the type of medications injected.&#xD;
      Subsequently, the patients were put in the supine position, and given oxygen 3 L/minutes by&#xD;
      nasal prongs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2021</start_date>
  <completion_date type="Anticipated">June 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel assignment</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>double (participant and outcome assessor)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of postdural puncture headache</measure>
    <time_frame>48 hours after spinal anesthesia</time_frame>
    <description>prevention of postdural puncture headache after spinal anesthesia in the first 48 hours postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of sensory block</measure>
    <time_frame>4 hours from injection of drug in subarachnoid space.</time_frame>
    <description>Duration of sensory block after spinal anesthesia from injection of drug till regain of sensation at level of T10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Postdural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>intravenous dexamethazone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive intrathecal 3 ml heavy bupivacaine 0. 5% +1 ml normal saline + intravenous 8 mg dexamethazone in 10 ml saline,to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intrathecal dexamethazone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive intrathecal 3 ml heavy bupivacaine 0.5% + 4 mg (1 ml) dexamethazone + intravenous 10 ml normal saline to prevent postdural puncture headache. Spinal anesthesia will be done in a sitting position under complete aseptic techniques, 25 G Quincke needle was inserted intrathecally at L3-L4 or L4-L5 interspace through midline approach. The study drugs were given by an anesthesiologist not aware of the type of medications injected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intravenous</intervention_name>
    <description>Evaluation of intravenous dexamethazone in prevention of postdural puncture headache</description>
    <arm_group_label>intravenous dexamethazone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone intrathecal</intervention_name>
    <description>Evaluation of intrathecal dexamethazone in prevention of postdural puncture headache</description>
    <arm_group_label>intrathecal dexamethazone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ASA I or II undergoing lower limb surgeries under spinal anesthesia&#xD;
&#xD;
          -  Patients ASAI or II undergoing lower abdominal surgeries under spinal anesthesia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgeries.&#xD;
&#xD;
          -  Patients with uncompensated heart diseases.&#xD;
&#xD;
          -  Patients with coagulopathy.&#xD;
&#xD;
          -  Presence of infection at site of injection of spinal anesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashraf Elagamy, E</last_name>
    <phone>oo2o224701953</phone>
    <email>elagamy_ashraf@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dalia Elfawy</last_name>
    <phone>0020100401092</phone>
    <email>daliamfawy@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ashraf Elsayed Elagamy</investigator_full_name>
    <investigator_title>Assisstant professor Anesthesia,Intensive care and pain management</investigator_title>
  </responsible_party>
  <keyword>intravenous dexamethazone</keyword>
  <keyword>intrathecal dexamethazzone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

